Introduction
Acquired immunodeficiency syndrome (AIDS) caused by the human immunodeficiency virus (HIV) is considered one of the most serious public health challenges on a global scale. Despite the great efforts that are being devoted to prevent, treat, and to better understand the disease, it remains one of the main causes of morbidity and mortality worldwide. It is estimated that over 35 million people were living with HIV in 2012, 2.3 million became newly infected and 1.6 million lost their lives as a result of AIDS (UNAIDS Report on the Global AIDS Epidemic 2013).
1 Of the two major types of HIV, HIV-1 and HIV-2, the former is the cause of worldwide epidemic of AIDS. HIV-1 causes the loss of CD4 + T-cells by direct killing or impairing function of these cells consequently leading to the cell destruction by apoptosis. 2 The combined therapy (highly active antiretroviral therapy, HAART) using synthetic reverse transcriptase (RT) and protease inhibitors has effectively suppressed virus replication and significantly prolonged the life of AIDS patients. However, the appearance of resistant viruses to these current drugs has created an urgent need for the discovery and development of potent anti-HIV drugs with novel modes of action. 3 Plant-associated microorganisms, especially endophytic fungi, are rich sources of novel and bioactive secondary metabolites. 4 As a part of our studies on arid land plants and their associated microorganisms for novel and/or biologically active small-molecule natural products, 5 and encouraged by the reports of the occurrence of metabolites with anti-viral activity in endophytic fungi, 6 we screened a small library of 100 extracts derived from endophytic fungal strains inhabiting the Sonoran desert plants for their anti-HIV activity. Our strategy involved culturing of these fungi in a variety of culture media, extraction of cultures with EtOAc, screening of the resulting extracts for cytotoxicity to T-lymphocytes (A3.01 cells). Those extracts showing ⩽25% toxicity were evaluated for their effects on viral replication in an assay using A3.01 cells infected with the HIV-1 LAV strain (lymphadenopathy-associated virus) in the presence of the extracts. Of the extracts evaluated by the application of this strategy, an EtOAc extract derived from the endophytic fungus Alternaria tenuissima, isolated from the living stem tissue of Quercus emoryi (Emory oak), exhibited promising activity and was selected for further investigation. Bioactivity-guided fractionation of this extract as described previously 7 and outlined in the Experimental section resulted in the isolation of two new metabolites, named altertoxin V (1) and altertoxin VI (2) in addition to previously known altertoxins I (3), II (4), and III (5) ( Fig. 1) . Herein we describe the structure elucidation of 1 and 2, and anti-HIV activities of 1 and3-5. Alternaria tenuissima is a saprophytic fungal pathogen inhabiting various plant species. 8 It is found widespread in the environment. 9 (Table 1 and Table 2 , respectively), also encountered in this work suggested the presence of a common carbon skeleton in all these metabolites. ( Table 1 and Table 2 ; Fig. 3 ); the downfield shift observed for C-6b (δ 45.0) of 4 may be attributed to the deshielding effect of C 6a -OH. Furthermore, the vicinal coupling between H-6 and H-6a (J 6,6a = 9.0 Hz) suggested that H-6 and H-6a in 1 have axial orientations. The cis-orientation of H-6a and H-6b was inferred from the small vicinal coupling (J 6a,6b = 2.5 Hz) between them. Since H-6 and H-6a aretrans-diaxial, the configuration of 6-OH should be β-equatorial. It was supported by the presence of almost superimposable 13 C and 1 H NMR peaks due to the 6-hydroxytetralone portion of 1 and the corresponding 7-hydroxytetralone portion of 3 as well as the reported data for related perylene oxides ( Table 1 and Table 2 ; Fig. 3 ). 6 Based on the foregoing evidence, the structure of altertoxin V was established as (6R,6aR,6bS,7R,8S)-3,6,10-trihydroxy-4,9-dioxo-4,5,6,6a,6b, 7,8,9-octahydro-7,8-epoxyperylene (1). The position (C-5/C-6) of this double bond was evident from the downfield chemical shifts observed for H-6a to δ 2.56 (br s) and H-6b to δ 3.79 (br s) as compared with 1 which contains an OH group at C-6. The 1 H NMR resonances of the rest of the protons of 1 and 2 were very similar ( Table 1 ). No vicinal coupling between H-6b (δ 3.79) and H-7 (δ 4.25) was observed which required the dihedral angle between these protons to be approximately 90° suggesting a β-configuration for the oxirane ring in 2. 14, 15 and 16 Thus the structure of altertoxin VI was determined as (6aR,6bR,7R,8S)-3,10-dihydroxy-4,9-dioxo-4,6a,6b,7,8,9-hexahydro-7,8-epoxyperylene (2). The remaining metabolites were identified as altertoxins I (3), 14 II (4), 14 and 20 and III (5), 14 by comparison of their spectroscopic data with those reported for these compounds.
All metabolites encountered were evaluated for their ability to inhibit HIV-1 viral replication in A3.01 infected cells. Based on their cytotoxicity to A3.01 cells, compounds 1-3 and 5 were tested at a concentration of 1.5 μg/mL whereas 4 was tested at 0.5 μg/mL. At these concentrations 1 and 3-5 inhibited viral replication almost completely (97-99%) while 2 caused only 33% inhibition on the peak day of virus production. The reduced effectiveness of 2 was probably due to its instability in the cell culture medium. Remarkably, the inhibition exhibited by active compounds 1 and 3-5 was similar or better than to that shown by AZT at 20 μM, the positive control used for this assay (Fig. 4) . In order to determine the minimum concentration required for complete inhibition of viral replication, each compound was tested at decreasing concentrations until viral replication was observed. Anti-viral activity was determined 9 days post-infection, the day of peak viral replication in the untreated control (see Fig. 4 ). As shown in Figure occur only at cytotoxic concentrations, 21 coupled with the observation of no negative effects on cell morphology or viability at concentrations used in our studies suggest that they have the potential to be developed as effective anti-HIV agents. Using a combination of the IC 50 and cytotoxicity data, the therapeutic indexes for altertoxins I (3), II (4), III (5), and V (1) were determined to be 3, 6.5, 15 and 50, respectively. While these indexes are low, they do provide a narrow window for further development and suggests that epoxyperylene structure may serve as a promising scaffold that could be further manipulated to afford potent and non-toxic anti-HIV therapeutics. 
Experimental

General experimental procedures
Optical rotations were measured with a JASCO Dip-370 polarimeter using MeOH or CHCl 3 as solvent. 1D and 2D NMR spectra were recorded in CDCl 3 , acetone-d 6 , or DMSO-d 6 using residual solvent peaks as internal standards with a Bruker DRX-500 instrument at 500 MHz for 1 H NMR and 125 MHz for 13 C NMR. The chemical shift values (δ) are given in parts per million (ppm), and the coupling constants are in Hz. UV spectra were recorded on a Shimadzu UV-160 UV-vis spectrometer. Low resolution and high resolution MS were recorded on Shimadzu LCMS QP8000α and JEOL HX110A spectrometers, respectively.
Antiviral activity evaluation
The experimental procedures for cytotoxicity and anti-HIV assays and determinations of doseresponse curves for compounds 1 and 3-5 have been described previously. (2) A yellow unstable solid; it was soluble in CDCl 3 to give yellow solution, which was found to be unstable and turned into a black solution within about an hour and deposited insoluble black particles after a few hours at 0 °C. 1 H NMR data see C NMR data, see Table 1 and Table 2 , respectively. C NMR data, see Table 1 and Table 2 
